Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells.
about
Intestinal permeability--a new target for disease prevention and therapyThe human neonatal gut microbiome: a brief reviewLactobacillus casei prevents impaired barrier function in intestinal epithelial cellsCan probiotics modulate human disease by impacting intestinal barrier function?Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeabilityLactobacillus plantarum (VR1) isolated from an ayurvedic medicine (Kutajarista) ameliorates in vitro cellular damage caused by Aeromonas veronii.Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrityL. plantarum prevents enteroinvasive Escherichia coli-induced tight junction proteins changes in intestinal epithelial cellsConsumption of a fermented dairy product containing the probiotic Lactobacillus casei DN-114001 reduces the duration of respiratory infections in the elderly in a randomised controlled trial.Probiotic engineering: towards development of robust probiotic strains with enhanced functional properties and for targeted control of enteric pathogens.Effect of Bacillus subtilis on Aeromonas hydrophila-induced intestinal mucosal barrier function damage and inflammation in grass carp (Ctenopharyngodon idella).Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study. A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial.Keratinocyte growth factor improves epithelial structure and function in a mouse model of intestinal ischemia/reperfusionGut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier functionUremia and chronic kidney disease: the role of the gut microflora and therapies with pro- and prebiotics.The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiotaGut ecosystem: how microbes help us.Differential targeting of the E-Cadherin/β-Catenin complex by gram-positive probiotic lactobacilli improves epithelial barrier functionThe role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development.Association between Polycystic Ovary Syndrome and Gut Microbiota.Effects of Supplementation of the Synbiotic Ecologic® 825/FOS P6 on Intestinal Barrier Function in Healthy Humans: A Randomized Controlled Trial.Gastrointestinal microbiota and some children diseases: a review.Role of probiotics in short bowel syndrome in infants and children--a systematic review.Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease.Protection and Restitution of Gut Barrier by Probiotics: Nutritional and Clinical Implications.Bifidobacterium bifidum improves intestinal integrity in a rat model of necrotizing enterocolitis.Effect of probiotics on intestinal barrier function.Probiotic Microorganisms Inhibit Epithelial Cell Internalization of Botulinum Neurotoxin Serotype A.Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agentsProbiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.Early life: gut microbiota and immune development in infancy.Effect of lactobacilli on paracellular permeability in the gutA review of the pharmacobiotic regulation of gastrointestinal inflammation by probiotics, commensal bacteria and prebiotics.Role of endogenous microbiota, probiotics and their biological products in human healthAntimicrobial Activity of Lactobacillus spp. Isolated From Fecal Flora of Healthy Breast-Fed Infants Against Diarrheagenic Escherichia coli.Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials.Probiotics and the Gut Immune System: Indirect Regulation.Intestinal barrier dysfunction: implications for chronic inflammatory conditions of the bowel.Effects of the Probiotic Enterococcus faecium and Pathogenic Escherichia coli Strains in a Pig and Human Epithelial Intestinal Cell Model.
P2860
Q27015884-A1806A6A-47AB-4BB5-930F-E3079F846EFEQ28080685-94E7ABBA-96FF-408E-BF95-3A06D42C840AQ28300177-5E083D7A-55FC-4287-B847-FE8218E34C1DQ28817192-CBB18B87-427E-4019-A168-AFB9D452A8DCQ29617378-E9B15D7F-8863-40C3-97D0-C810AE4D79B0Q31021479-53B451F2-48E1-4447-870D-D2A991760831Q33309955-50DB70DF-BDB7-4626-965B-3AF28AB92550Q33424095-2C13E578-9A98-48FB-A121-8057CCE19F85Q33502385-4E36E34A-34B5-4C22-AC27-FAC4C5BE9261Q33651733-CFECEF63-103A-4B21-AC65-6833D9F379B0Q33685620-826A112F-AC46-4C8A-9C19-6BFF900B984CQ34005969-0190D1C8-2337-4306-98FD-83F244AB8EF7Q34427411-6DD93545-5F9E-40C5-A2EA-4BAB492D9B16Q34499017-27FA49B3-C6D5-4A15-8946-666C1EE4511AQ34587671-D1D039D9-95DE-48B1-B514-C93ED5610E91Q34602194-DC83F8A2-1D85-4622-9E78-122CCFADCF75Q34647328-E29965B4-5735-4D11-A0DA-DBEEAA3D3D52Q35105266-21BED7C4-E9B7-45C8-8027-537B5C8F606FQ35739226-FA468AA9-3A62-4F4B-981A-C80F7B8D231BQ35953201-9A16550A-B31A-4691-9F1A-FD2B11A70483Q35993883-C8C47511-F2F5-4A0B-AE88-9691A9E5706EQ36218453-ACE205EF-150B-4BA3-8D55-E25960BA0E65Q36415190-A43D837D-68B1-45F9-B5D5-2672671D028BQ36993969-E819F155-3C1C-4C3F-B313-DE398404435CQ37019506-17851EF8-26D5-4CD5-B211-2E8D666BAA2AQ37396622-3B948575-82D9-45BB-B64A-06F768F00607Q37421142-7A466249-5424-469E-8C59-B75F0CE8A408Q37524266-0027EB30-96E3-42C6-BACB-7B0E91A078A2Q37543639-6B13DA52-E61D-48B4-995D-6898284A231EQ37712802-50B4B513-44DB-4D43-B15E-1BFAD6D67CDBQ37723991-0AEAEED3-9378-448F-A157-43915343BBB2Q37915055-A31ED372-614F-4A92-9954-834BB5FD9EC2Q37976700-9CE3AEE0-4767-463D-93F7-ACE5D09B4E6BQ37994645-08156845-E95A-4521-967F-B246AA1BA8D5Q38073062-80DC0CF4-DE13-4BB9-AEC6-3D561FF49D8EQ38282748-EDA67C59-56A3-4F88-83D0-55DDC8D0DBD0Q38548793-A2C932BB-6EBF-4806-97AA-D0838663113AQ38598371-A631B969-19EC-4FDC-92CF-EE930019D96BQ38810502-96524621-A799-46AF-A827-54F45C15C643Q39438135-AF1F9752-9FDA-4522-93C9-9CD8D47DEF29
P2860
Lactobacillus casei DN-114 001 inhibits the increase in paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Lactobacillus casei DN-114 001 ...... ichia coli-infected T84 cells.
@en
type
label
Lactobacillus casei DN-114 001 ...... ichia coli-infected T84 cells.
@en
prefLabel
Lactobacillus casei DN-114 001 ...... ichia coli-infected T84 cells.
@en
P2093
P1476
Lactobacillus casei DN-114 001 ...... richia coli-infected T84 cells
@en
P2093
Karine Thoreux
Miguel Freitas
Nadège Parassol
Patrick Rampal
P304
P356
10.1016/J.RESMIC.2004.09.013
P577
2004-12-15T00:00:00Z